FMR LLC boosted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 2.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,917,684 shares of the biopharmaceutical company's stock after buying an additional 149,511 shares during the period. FMR LLC owned about 9.13% of Xenon Pharmaceuticals worth $272,349,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Logos Global Management LP acquired a new stake in shares of Xenon Pharmaceuticals during the 2nd quarter valued at about $14,621,000. Samlyn Capital LLC lifted its stake in Xenon Pharmaceuticals by 61.5% during the second quarter. Samlyn Capital LLC now owns 639,685 shares of the biopharmaceutical company's stock worth $24,941,000 after purchasing an additional 243,489 shares during the period. Point72 Asset Management L.P. boosted its holdings in Xenon Pharmaceuticals by 74.7% during the second quarter. Point72 Asset Management L.P. now owns 482,022 shares of the biopharmaceutical company's stock valued at $18,794,000 after purchasing an additional 206,163 shares in the last quarter. Affinity Asset Advisors LLC grew its stake in shares of Xenon Pharmaceuticals by 18.7% in the 2nd quarter. Affinity Asset Advisors LLC now owns 994,227 shares of the biopharmaceutical company's stock valued at $38,765,000 after purchasing an additional 156,840 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Xenon Pharmaceuticals by 188.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 212,287 shares of the biopharmaceutical company's stock worth $8,358,000 after buying an additional 138,685 shares in the last quarter. Institutional investors own 95.45% of the company's stock.
Insider Activity
In other news, Director Gary Patou sold 4,891 shares of the business's stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $41.08, for a total transaction of $200,922.28. Following the completion of the transaction, the director now directly owns 23,573 shares in the company, valued at approximately $968,378.84. The trade was a 17.18 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.52% of the stock is currently owned by company insiders.
Xenon Pharmaceuticals Stock Performance
NASDAQ:XENE traded down $0.30 on Monday, hitting $42.33. 119,848 shares of the stock were exchanged, compared to its average volume of 388,154. Xenon Pharmaceuticals Inc. has a 52 week low of $35.53 and a 52 week high of $50.99. The company's 50-day moving average price is $41.47 and its 200 day moving average price is $40.25.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($0.82) by $0.01. During the same quarter in the prior year, the company earned ($0.73) EPS. Equities analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.
Wall Street Analyst Weigh In
XENE has been the topic of several recent analyst reports. William Blair upgraded shares of Xenon Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. Raymond James reaffirmed an "outperform" rating and set a $50.00 price target on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Royal Bank of Canada reissued an "outperform" rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a research note on Tuesday, September 3rd. Cantor Fitzgerald restated an "overweight" rating and issued a $65.00 target price on shares of Xenon Pharmaceuticals in a research note on Friday, August 9th. Finally, Wedbush reduced their price target on shares of Xenon Pharmaceuticals from $50.00 to $49.00 and set an "outperform" rating on the stock in a research report on Friday, August 9th. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Xenon Pharmaceuticals currently has an average rating of "Buy" and an average price target of $57.45.
Read Our Latest Report on Xenon Pharmaceuticals
Xenon Pharmaceuticals Profile
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Articles
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
